Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 374 participants.
Also called NCT02068443
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 374 participants
- Sponsor
- Registry
-
NCT02068443 -
U1111-1151-6515
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02068443. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-06-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Alogliptin
- Intervention (Drug)
- Metformin hydrochloride
- Intervention (Drug)
- Metformin hydrochloride Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02068443- Content hash
99162ebd3b365757b1f642ab0c267035120bfd2aab77e0a23e65b9e21f7bdaa9